At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...
Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...
A home blood pressure telemonitoring program effectively reduced blood pressure in real-world clinical settings, but program enrollment expenses increased overall costs. Objectives: To evaluate the 12 ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
Objective: To determine whether industry payments to cardiologists are associated with Medicare beneficiary spending, as financial incentives may influence clinical deci ...
Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.
Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs. Green also highlights ...
Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...
As the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) wrapped up, leading HIV experts reflected on the ...
The rise in CRC in adults younger than 65 underscores the need for early screening and prevention efforts. The report’s ...
Following the CDC’s major revisions to the US childhood immunization schedule, Noel T. Brewer, PhD, distinguished professor ...
The management of smoldering multiple myeloma (MM) is undergoing a significant transformation, driven by growing evidence that early intervention can meaningfully delay progression to active disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results